Eton Pharmaceuticals: David Krempa sells 4,166 shares

Q: How many ETON shares did David Krempa sell, and at what price?

David Krempa sold 4,166 Eton Pharmaceuticals common shares on October 6, 2026, at a weighted average price of $55.0663 per share. The multiple-trade prices ranged from $54.915 to $55.135, and no Rule 10b5-1 plan is reported.

Q: What happened to David Krempa's ETON restricted stock units?

On October 2, 2026, David Krempa converted 10,522 restricted stock units into 10,522 common shares; 21,044 restricted stock units were reported after the transaction. The units came from a 42,088-unit grant on October 2, 2024, vesting in four equal annual installments beginning October 2, 2025.

The chief business officer's reported position included 21,044 restricted stock units after the October 2 conversion.

Filing Impact

(Moderate)

Filing Sentiment

(Negative)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Eton Pharmaceuticals, Inc. Chief Business Officer David Krempa sold 4,166 common shares on October 6, 2026, at a weighted average price of $55.0663 per share; the shares were sold in multiple trades at prices from $54.915 to $55.135. On October 2, 2026, he converted 10,522 restricted stock units into 10,522 common shares, with 21,044 restricted stock units reported after the transaction. The units were from a 42,088-unit grant made October 2, 2024, vesting in four equal annual installments beginning October 2, 2025.

Insider Trade Summary

Exercise and sale activity reported; no spread calculated

Exercise and Sale 3 txns

Insider Krempa David

Role Chief Business Officer

Sold 4,166 shs ($229K)

Approx. gross sale proceeds $229K

Approx. exercise cost $0.00

Type	Security	Shares	Price	Value
Sale	Common Stock ^{F1, F2}	4,166	$55.0663	$229K
Exercise	Restricted Stock Units ^F3	10,522	$0.00	$0.00
Exercise	Common Stock ^F3	10,522	--	--

Holdings After Transaction: Restricted Stock Units — 21,044 contracts (Direct); Common Stock — 43,381 shares (Direct)

Footnotes (3)

F1. The Reporting Person will provide upon request by the Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price.
F2. The shares were sold in multiple trades at prices ranging from $54.915 to $55.135. The price reported above reflects the weighted average sales price.
F3. On October 2, 2024, the reporting person was granted 42,088 restricted stock units which vest in four equal annual installments beginning October 2, 2025.

Key Figures

Common shares sold: 4,166 shares Weighted average sale price: $55.0663 per share Sale-price range: $54.915 to $55.135 per share +4 more

7 metrics

Common shares sold 4,166 shares October 6, 2026

Weighted average sale price $55.0663 per share October 6, 2026

Sale-price range $54.915 to $55.135 per share Multiple trades on October 6, 2026

Restricted stock units converted 10,522 units October 2, 2026

Common shares acquired 10,522 shares October 2, 2026

Restricted stock units after transaction 21,044 units Reported after the October 2, 2026 transaction

Restricted stock unit grant 42,088 units Granted October 2, 2024; vesting in four equal annual installments beginning October 2, 2025

Key Terms

Restricted Stock Units, weighted average sales price, vest in four equal annual installments

3 terms

Restricted Stock Units financial

"42,088 restricted stock units which vest in four equal annual installments"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

weighted average sales price financial

"price reported above reflects the weighted average sales price"

vest in four equal annual installments technical

"which vest in four equal annual installments beginning October 2, 2025"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many ETON shares did David Krempa sell, and at what price?

David Krempa sold 4,166 Eton Pharmaceuticals common shares on October 6, 2026, at a weighted average price of $55.0663 per share. The multiple-trade prices ranged from $54.915 to $55.135, and no Rule 10b5-1 plan is reported.

What happened to David Krempa's ETON restricted stock units?

On October 2, 2026, David Krempa converted 10,522 restricted stock units into 10,522 common shares; 21,044 restricted stock units were reported after the transaction. The units came from a 42,088-unit grant on October 2, 2024, vesting in four equal annual installments beginning October 2, 2025.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Available on EDGAR 10/06/2026 - 04:49 PM Accepted by SEC EDGAR 10/06/2026 - 04:49 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Krempa David

(Last)

(First)

(Middle)

C/O ETON PHARMACEUTICALS, INC.

21925 W. FIELD PARKWAY, SUITE 235

(Street)

DEERPARK

ILLINOIS

60010-7208

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Eton Pharmaceuticals, Inc. [ ETON ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Business Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
10/06/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	10/02/2026		M		10,522	A	⁽³⁾	47,547	D
Common Stock	10/06/2026		S		4,166	D	$55.0663⁽¹⁾⁽²⁾	43,381	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Restricted Stock Units	$0	10/02/2026		M			10,522	⁽³⁾	⁽³⁾	Common Stock	10,522	$0	21,044	D

Explanation of Responses:

1. The Reporting Person will provide upon request by the Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price.

2. The shares were sold in multiple trades at prices ranging from $54.915 to $55.135. The price reported above reflects the weighted average sales price.

3. On October 2, 2024, the reporting person was granted 42,088 restricted stock units which vest in four equal annual installments beginning October 2, 2025.

Remarks:

The reporting person has authorized and designated the named person to file this Form 4 on the reporting person's behalf for indefinite duration.

	/s/ Judith M Matthews	10/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR